We are live on
!
Find out more
DTC
Deep Track Capital Portfolio holdings
AUM
$6.12B
1-Year Est. Return
144%
This Fund
S&P 500
This Quarter
Est. Return
+39.07%
1 Year Est. Return
+144%
3 Year Est. Return
+348.41%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.38B
AUM Growth
+$198M
(+9.1%)
Cap. Flow
-$130M
Cap. Flow
% of AUM
-5.45%
Top 10 Holdings %
Top 10 Hldgs %
45.26%
Holding
80
New
15
Increased
16
Reduced
23
Closed
20
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Biogen
BIIB
|
+$84.7M |
| 2 |
Insmed
INSM
|
+$82.4M |
| 3 |
Sarepta Therapeutics
SRPT
|
+$61.2M |
| 4 |
Ionis Pharmaceuticals
IONS
|
+$50.7M |
| 5 |
AUTL
Autolus Therapeutics
AUTL
|
+$37.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NovoCure
NVCR
|
+$98.3M |
| 2 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$80M |
| 3 |
BioMarin Pharmaceuticals
BMRN
|
+$51.5M |
| 4 |
Kura Oncology
KURA
|
+$43.5M |
| 5 |
Aurinia Pharmaceuticals
AUPH
|
+$31.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 96.31% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Dyne Therapeutics
DYN
$4.15B
| $31.1M | 1.31% |
2,684,200
-500,000
| -16% | -$5.79M |
|
27
CALL
Ascendis Pharma A/S
ASND
$16.5B
| $30.4M | 1.28% |
249,300
-750,700
| -75% | -$87.2M |
|
28
Edgewise Therapeutics
EWTX
$4.28B
| $30.2M | 1.27% |
3,374,394
| – | – |
|
|
SLN
29
Silence Therapeutics
SLN
$546M
| $29.8M | 1.25% |
1,951,580
| – | – |
|
|
AUTL
30
Autolus Therapeutics
AUTL
$389M
| $28.5M | 1.2% |
+15,000,000
| New | +$37.9M |
|
|
ATXS
31
DELISTED
Astria Therapeutics
ATXS
| $27M | 1.14% |
+1,816,531
| New | +$18.7M |
|
|
VIGL
32
DELISTED
Vigil Neuroscience
VIGL
| $26.3M | 1.1% |
2,104,174
-259,014
| -11% | -$3.18M |
|
|
RAPT
33
DELISTED
RAPT Therapeutics
RAPT
| $25.8M | 1.08% |
+163,118
| New | +$26.1M |
|
|
ESPR
34
DELISTED
Esperion Therapeutics
ESPR
| $24.9M | 1.05% |
4,000,000
-1,636,587
| -29% | -$11.7M |
|
35
Nurix Therapeutics
NRIX
$2.45B
| $24.9M | 1.04% |
2,266,569
+212,948
| +10% | +$2.57M |
|
|
DVAX
36
DELISTED
Dynavax Technologies
DVAX
| $24.8M | 1.04% |
+2,327,951
| New | +$27M |
|
37
Intellia Therapeutics
NTLA
$1.51B
| $24.4M | 1.03% |
700,000
+400,000
| +133% | +$19M |
|
38
Acumen Pharmaceuticals
ABOS
$152M
| $21.3M | 0.9% |
3,952,000
+173,182
| +5% | +$1.16M |
|
|
39
BioMarin Pharmaceuticals
BMRN
$11.9B
| $19.6M | 0.82% |
189,800
-549,063
| -74% | -$51.5M |
|
40
Crinetics Pharmaceuticals
CRNX
$8.88B
| $19.2M | 0.81% |
1,048,829
-4,171
| -0.4% | -$73.5K |
|
41
Geron
GERN
$898M
| $17.9M | 0.75% |
+7,414,693
| New | +$16.6M |
|
42
Heron Therapeutics
HRTX
$93.4M
| $16.2M | 0.68% |
6,496,976
-2,051,411
| -24% | -$6.61M |
|
43
Nuvation Bio
NUVB
$2.29B
| $15.8M | 0.66% |
8,221,188
-1,104,352
| -12% | -$2.23M |
|
44
Syndax Pharmaceuticals
SNDX
$1.7B
| $12.7M | 0.53% |
+500,000
| New | +$11.7M |
|
45
Relmada Therapeutics
RLMD
$540M
| $9.9M | 0.42% |
2,837,818
+2,376,957
| +516% | +$20.9M |
|
46
Protagonist Therapeutics
PTGX
$8.55B
| $9.51M | 0.4% |
+871,493
| New | +$7.35M |
|
47
Nkarta
NKTX
$152M
| $8.11M | 0.34% |
1,354,200
-1,460,644
| -52% | -$14.7M |
|
|
RNAM
48
DELISTED
Avidity Biosciences
RNAM
| $6.66M | 0.28% |
+300,000
| New | +$4.47M |
|
49
Viking Therapeutics
VKTX
$3.88B
| $5.73M | 0.24% |
+610,083
| New | +$2.72M |
|
50
Fulcrum Therapeutics
FULC
$241M
| $5.6M | 0.23% |
768,607
-132,104
| -15% | -$861K |
|
Similar funds
AWA
ACM
CIS
AA
JWBC
EMPI
HPG
B
Deep Track Capital's Q4 2022 Portfolio in Review
As of Q4 2022, Deep Track Capital held 80 positions worth $2.38B, up 9.1% from $2.18B the previous quarter. Its ten largest holdings account for 45% of the portfolio.
Deep Track Capital withdrew a net $130M in Q4 2022, closing 20 positions and reducing 23 holdings. Its most notable exit was NovoCure, an estimated $98.3M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 93% a quarter earlier.
Against the trend, Deep Track Capital opened a new position in Biogen worth $83.1M.
- Deep Track Capital's largest Q4 2022 buy was Biogen: 300,000 shares worth $83.1M.
- Deep Track Capital added most to DICE Therapeutics, Inc. Common Stock in Q4 2022, an estimated $23.9M increase.
- Deep Track Capital's biggest Q4 2022 reduction was Horizon Therapeutics Public Limited Company Ordinary Shares, cutting an estimated $80M.
- Deep Track Capital fully exited NovoCure in Q4 2022, selling an estimated $98.3M.
- Deep Track Capital's ten largest holdings make up 45% of its $2.38B portfolio in Q4 2022.
- Deep Track Capital opened 15 new positions and closed 20 in Q4 2022.
- Deep Track Capital's portfolio value rose 9.1% quarter-over-quarter to $2.38B.
Based on Deep Track Capital's 13F filing for Q4 2022, filed 14 Feb 2023.